Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Brian Abrahams

Regeneron Pharmaceuticals Dives On $1.1 Billion Deal To Rival Merck In Cancer

Regeneron stock tumbled Thursday after the company announced a deal to acquire the international rights to Sanofi-partnered cancer drug Libtayo.

Investors Business Daily

Biotech Stocks Hammered On Roche's Unexpected Failure In Lung Cancer

A Roche failure in lung cancer sent a ripple through biotech stocks on Wednesday, toppling Arcus, BeiGene, Iteos and others.

Investors Business Daily

Biogen Pops After Eisai Asks FDA To Approve A New Alzheimer's Treatment

Biogen stock popped Tuesday after the company's partner, Eisai, finished submitting its application for an experimental Alzheimer's drug.

Investors Business Daily

From analysis to the latest developments in health,
read the most diverse news in one place.

Intercept Pharma Scores $450 Million Deal For Its Flagship Liver Drug

Intercept sold the international rights to its liver-disease treatment, Ocaliva, for up to $450 million on Thursday, and ICPT stock soared.

Investors Business Daily

How Medicare 'Snuffed Out' Hope For Biogen's Controversial Alzheimer's Drug

Medicare officially restricted use of Biogen's Alzheimer's treatment, Aduhelm, to patients enrolled in clinical studies.

Investors Business Daily

Biogen Snags Upgrade On Alzheimer's Hopes, And Then Announces Layoffs

Biogen stock popped Thursday after an analyst suggested it could reap $8 billion in sales of its Alzheimer's treatments.

Investors Business Daily

1 2 3

People

Brian Abrahams

56 stories

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Regeneron Pharmaceuticals

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.